UNCSTD第22届副主席致外国专家和国际友人的信

尊敬的外国专家和朋友:

在世界各国友人的关心和支持下，中国人民众志成城、科学防治，目前疫情防控形势积极向好，多个省市实现了连续多日新病例零增长。在确保疫情防控到位的前提下，我国政府有序推动企事业单位复工复产，降控经济发展影响，为世界经济繁荣与稳定提振信心。

在这场斗争中，中国广大科技工作者奋战在抗击疫情科研攻关第一线，取得了一些科研成果，在疫情防控中发挥了积极作用。本着公开、透明、真诚态度，我们积极主动同世卫组织和国际社会开展科研合作和信息交流，努力防止疫情在世界蔓延。在此，我谨向大家介绍我所在的广东省近期为疫情防控和医疗救治提供技术支撑的几项成功实践，愿与其他国家分享、对接、合作和提供服务：

一是试用新冠肺炎AI辅助诊断系统。众所周知，影像学检查在新冠肺炎的诊疗中具有非常重要的参考价值。新冠肺炎属于新发疾病，病程发展快，需要对患者拍摄多次CT以对患者进行确诊、监测病情发展、评估治疗效果等，单纯凭借肉眼阅片医生很难快速对比并识别病灶变化。广州再生医学与健康广东省实验室联合中山大学孙逸仙纪念医院在50万份临床影像学大数据的基础上，紧急开发了基于胸部CT和X-ray影像学的新冠肺炎AI辅助试行诊断系统，能够高效、特异区分出新冠肺炎患者和非新冠肺炎患者（包括其他病毒性肺炎、细菌性肺炎和其他发热患者）。基于CT图像诊断新冠肺炎准确率为90%，可在20秒内完成一例CT图像的检测。目前该系统已利用云平台实现多点部署，在中国多个省市开展AI辅助诊断。在互联网上登录http://ncov-ai.big.ac.cn/即可注册使用该试用辅助诊断系统，首页用户手册中附有注册联系方式和技术支持联系方式。

Distinguished foreign experts and friends:

With the concern and support from friends all over the world, the COVID-19 containing in China shows a positive trend. The Chinese people fight against the epidemic in a united and scientific way. A number of provinces and cities witness continuous zero-increase of newly con firmed cases. On the premise of ensuring epidemic prevention and control, the Chinese government helps enterprises and institutions to resume production and operation. Every effort is made to minimize the negative impact on economic development and boost confidence in prosperity and stability of the world's economy.

In this battle, our scientific and technological practitioners work hard at the forefront of related research projects. Some amazing achievements have exerted active effects in the epidemic prevention and control. The Chinese government from the start acts in an open, transparent and honest manner, and shares information and research progress with World Health Organization (WHO) and the international community. We make all efforts to prevent the epidemic from spreading. Here, I would like to introduce some successful practices in Guangdong province, where I live and work.They are proved to be effective in epidemic control and medical treatment.We are happy to share with you all for exchange and cooperation and provide related services if needed.

First, trial of AI-aided COVID-19 Diagnostic System. Imageological examination plays an important role in the diagnosis of novel coronavirus pneumonia. The epidemic is a newly emerging disease featured with rapid deterioration. CT scans are repeatedly used to confirm cases, monitor disease progression and evaluate therapeutic effect. However, it is hard for doctors to make quick comparison and lesion change recognition only through visual examination. Based on about 500,000 clinical images, Guangzhou Regenerative Medicine and Health Guangdong Laboratory and Sun Yat-Sen Memorial Hospital af filiated with Sun Yat-Sen University work together to develop the AI-aided COVID-19 Diagnostic System. Featured with chest-CT and X-ray imageology, the System can differentiate COVID-19 patients from non-COVID-19 patients ef ficiently and speci fically (including patients of other viral pneumonia, bacterial pneumonia or other patients with fever). It can complete the detection of one CT scan in 20 seconds with the diagnostic accuracy of 90%. In China, it has been deployed in many provinces and cities to aid the diagnosis through cloud platform. If needed, please check the website http://ncov-ai.big.ac.cn/ and register for the trial of the AI-aided diagnostic system. Contact for registration and technical support can be found in the User's Manual on the homepage.

二是云脑支持科研抗疫。广东鹏城实验室拥有国内首个人工智能基础开源开放平台——鹏城云脑，现有AI算力100P FLOPS@FP16（每秒十亿亿次半精度浮点计算）。在疫情期间，任何针对本次新型冠状病毒的基因测序、蛋白筛选、疫苗和药物研发的公共科研机构、学校、医院都可以通过邮件anti-2019-nCoV@pcl.ac.cn联系鹏城实验室，并提交研究的主要方向和预期成果，鹏城实验室有专人在第一时间回复，由专业评估小组进行方案评估，并为评估通过的研究方案免费提供相应的AI算力支持。欢迎世界各国广大科研人员提出最新的研究方案，共同为抗击新型冠状病毒贡献力量。目前，鹏城实验室云脑平台提供的算力支持，已推动中国在病毒传播预测、药物筛选与疫苗研发、临床早期诊断等方面取得多项进展，相关病毒传播预测模型已开始试点应用，算力支持的药物筛选发现一些老药对新冠病毒具有良好体外活毒对抗效果，加速了临床试验的开展。

2020年3月19日，时任广东省科技厅厅长王瑞军（右二）在广东科学中心调研隔离椅和隔离诊台

Second, Cloud Brain supporting anti-epidemic research. Peng Cheng Cloud Brain under Peng Cheng Laboratory is the first open source platform in China based on arti ficial intelligence with the AI computing power of 100 PFLOPS @ FP16. During the epidemic, the public research institutions, universities and hospitals involved in coronavirus-related gene sequencing, protein screening, vaccine and drug R&D are welcome to contact Peng Cheng Laboratory (anti-2019-nCoV@pcl.ac.cn) and submit scheme description of research direction and expected outcomes. Peng Cheng Laboratory will give a reply as soon as possible. The professional evaluation panel will provide a scheme evaluation accordingly and the approved proposals will be supported by free AI computing power.We welcome researchers worldwide to work together to fight against coronavirus. The computing power support of Peng Cheng Cloud Brain Platform has so far promoted the development progresses in terms of virus transmission prediction, drug screening, vaccine R&D, early clinical diagnosis, etc. Moreover, pilot application of related virus transmission prediction models has been carried out. With the assistance of the computing power, drug screening results show that some existed drugs have positive in vitro anti-viral effect upon COVID-19 virus. It accelerates the process of clinical trials.

Third, the detecting products for COVID-19. Real-Time Fluorescent RTPCR Kit for Detecting the 2019 Novel Coronavirus developed by BGI Group Co., Ltd. has been applied in more than 20 countries worldwide.BGI is capable of producing 200,000 PCR test reagents, 10,000 sequencing test reagents and 500,000 antibody test reagents on a daily basis. With 14 Huo-Yan Laboratories to do the emergency detecting, the nucleic acid/ antibody test of BGI is up to 50,000 reagents per day (Email: info@bgi.com, Contact: Yunping Zheng, Mobile: +86 13600002151). The COVID-19 Nucleic Acid Detection Kit (PCR-fluorescence method), developed by DAAN Gene Co., Ltd. of Sun Yat-Sen University, is among the first batch of COVID-19 detection products registered and approved in China. The accumulated output is almost 5 million reagents, which have been used extensively to detect the novel coronavirus (Email: alice@daangene.net,Contact: Yongmei Jin, Mobile: +86 18620055688). The COVID-19 Antibody Detection Kit (Lateral Flow Method), developed by Guangzhou Wondfo Biotech Co., Ltd., is the first antibody detection reagent approved in China which is capable of detecting novel coronavirus antibody in human serum, plasma, and whole blood. There are also 3 Wanfo antibody detection kits granted the CE certi fication in Europe, i.e. Wondfo SARSCoV-2 Antibody Test (Lateral Flow Method), Finecare SARS-CoV-2 IgM Test, Finecare SARS-CoV-2 Antibody Test (Email: pm@wondfo.com.cn,Contact: Fei Chen, Mobile: +86 13632361458).

三是新冠病毒检测技术产品。深圳华大生物科技有限公司研制的新型冠状病毒核酸检测试剂盒（荧光PCR法），已经在全球20多个国家得到应用，该公司拥有日产20万人份PCR检测试剂、1万人份测序检测试剂、50万人份抗体检测试剂的能力，拥有14个“火眼”实验室，每天能够完成5万人份核酸或抗体检测能力（邮箱：info@bgi.com，联系人：郑云平，电话：13600002151）。中山大学达安基因股份有限公司研制的新型冠状病毒核酸检测试剂盒（荧光PCR法），为中国国内首批获得注册审批的新冠病毒检测技术产品，目前累计生产了近500万人份，广泛用于新型冠状病毒的检测（邮箱：alice@daangene.net，联系人：金咏梅，电话：18620055688）。广州万孚生物技术股份有限公司研制的新型冠状病毒抗体检测试剂盒（胶体金法），为中国国内获批的首个抗体检测试剂，能够检测人血清、血浆、全血中的新型冠状病毒抗体；该公司还有3个新型冠状病毒抗体检测试剂获欧盟CE准入资格，分别为Wondfo SARS-CoV-2 Antibody Test（Lateral Flow Method）、Finecare SARS-CoV-2 IgM Test、Finecare SARS-CoV-2 Antibody Test（邮箱：pm@wondfo.com.cn，联系人：陈飞，电话：13632361458）。

四是院感防控新设备。广州安捷生物安全科技股份公司（钟南山院士产学研团队成员）针对新冠肺炎疫情的防控，提出“单人隔离、即时消杀”的创新研发理念，自主创新研制了一系列隔离防控器械产品：负压隔离病床、医用隔离诊台、隔离净化椅、开放式隔离病床、儿童隔离病床等。在本次疫情期间，该批产品在广东省人民医院、中山一院、广医一院、301海南医院等各大医疗机构的发热门诊、呼吸科/传染科病房、候诊大厅、输液厅、隔离区、机场、出入境海关等呼吸感染相关场所应用，隔离防控的效果明显、获得用户高度的认可和好评。产品特点是持续即时收集和处理单个病人呼吸的可能带病原气体，即时消除、防控病人与其他易感人群之间的传染，可阻断呼吸传染病传播，减少感染发生。该公司欢迎世界各国的医疗机构联系对接，可合作共建当地的呼吸传染隔离防线，也欢迎一些设备生产企业对接联合加盟生产（CLG86@163.com）。

Fourth, new equipment for hospital infection prevention. Focusing on the prevention and control of COVID-19, Guangzhou Angel Biosafety Science and Technology Co., Ltd. (member of the industry-universityresearch team of Dr. Nanshan Zhong) puts forward the innovative R&D concept of “solo quarantine, immediate sterilization”. With this concept, a series of products used for quarantine, prevention and control are developed, including the hospital beds for negative pressure quarantine/open quarantine/children quarantine, the medical isolation diagnosis table, the isolation purification chair, etc. These products have been applied at places with higher risk of respiratory infections,including airports, customs and fever clinics, pneumology/infectious departments, waiting halls, infusion halls, isolation areas of the medical institutions, e.g. Guangdong Provincial People’s Hospital, the First Af filiated Hospital, Sun Yat-Sen University, the First Af filiated Hospital of Guangzhou Medical University, Hainan Hospital of PLA General Hospital. The application performance of these equipment are signi ficant in the epidemic prevention and control, and are highly recognized and praised by the users. The feature of the products is to collect and process the expired gas instantly and constantly from the individual of con firmed cases which could carry pathogen. It can ef ficiently eliminate and control the possibility of person-to-person transmission between patients and susceptible population. In this way, it helps to block the spread of respiratory infectious diseases and reduce the incidence of infection. Medical institutions around the world are welcome to contact the company (CLG86@163.com) to co-build the defense line to prevent local respiratory infection. Manufacturers are also welcome to join the equipment production.

Fifth, the washable protective masks for civil use. Advanced Energy Science and Technology Guangdong Laboratory develops a kind of washable protective masks for civil use based on the heavy ion technology. Such mask is made of the washable heavy ion microporous membrane material instead of the melt-blown fabric which is in short supply during the epidemic. The air could go through the tiny holes on the microporous membrane material and the aerosol and bacteria will be blocked with no need to spray any other chemical reagents. Tested by the authority institute, PFE of such mask can reach 76.6%, considerably higher than the 30% standard of medical surgical mask. The Laboratory is open to the researchers, enterprises and organizations worldwide to improve the performance of the product. Purchase orders from other countries are welcome. For details, please contact the Laboratory(modan@impcas.ac.cn).

五是可清洗民用防护口罩。先进能源科学与技术广东省实验室利用重离子技术开发了可清洗民用防护口罩。该口罩不采用市面紧缺的熔喷布，而是采用可水洗的重离子微孔膜材料，通过膜上细微的小孔达到通过空气、阻拦气溶胶和细菌的目的，无须喷涂任何化学试剂。经权威机构检测，该口罩的颗粒过滤效率可达76.6%，远高于医用外科口罩颗粒过滤效率30%的标准。该实验室欢迎世界各国广大科研人员和企业、团体对接共同研发不断提升产品性能，同时也支持国外供货商采购产品，疫情期间可以通过邮件modan@impcas.ac.cn联系实验室。

六是临床试用药物。磷酸氯喹（简称氯喹）具有广泛抗病毒及抗冠状病毒的作用，临床研究结果显示氯喹或可提高新冠肺炎患者的救治成功率、缩短住院时间及改善预后。在广东省磷酸氯喹治疗新冠肺炎的临床试用研究中，累计入组磷酸氯喹治疗新冠肺炎患者120例，其中轻型9例，普通型107例，重型4例，平均用药后4.4天转阴，无1例发展为危重型，目前已出院81例。用药过程中，暂未发现严重不良反应。磷酸氯喹被纳入国家卫健委、中医药局发布的《新型冠状病毒肺炎诊疗方案（试行第六版）》（http://www.nhc.gov.cn/yzygj/s7 653p/202002/8334a8326dd94d329df351d7da8a efc2.shtml.）以及2月29日广东省药事管理质量控制中心发布的《新型冠状病毒肺炎临床合理用药广东专家共识（第二版）》（https://mp.weixin.qq.com/s/MiRwtFYbJy3u-0P0V-CbWw）。可以通过邮件shanpingjiang@126.com联系江山平教授科学指导磷酸氯喹的用药使用。

当前，中国疫情暴发态势得到有效遏制，全球新冠疫情却呈现快速增长态势，多国确诊病例不断上升，国际疫情防控形势严峻。我们对于疫情在世界其他国家的蔓延感同身受，真诚愿与各国分享科研成果、交流经验，深化国际科技合作，竭尽全力帮助其他国家抗击疫情。

“孤举者难起，众行者易趋。”这次疫情再次给国际社会带来深刻启示：我们的命运紧密相连，休戚相关。让我们守望相助，携手抗疫，早日打赢这场阻击战。

祝您幸福安康！

联合国科技促进发展委员会（UNCSTD）第22届副主席广东省韶关市人民政府市长，原广东省科学技术厅厅长王瑞军 博士

(广东省科技厅供稿）

Sixth, drugs for clinical trials. Chloroquine phosphate (chloroquine) has a wide range of antiviral effects, including anti-coronavirus. Results of clinical research show that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome.According to the statistics, 120 patients were enrolled in the chloroquine treatment group in the clinical trial research in Guangdong, of which 9 mild cases, 107 ordinary cases, 4 severe cases; the patients were tested negative after drug treatment for 4.4 days on average with none of them developed into critical case, and 81 cases were discharged from hospital.So far, there is no serious adverse reaction observed in the medication.The drug (chloroquine) is included in the Guidelines for the Prevention,Diagnosis, and Treatment of Pneumonia Caused by COVID-19 (Trial Edition 6) issued by the National Health Commission and the National Administration of Traditional Chinese Medicine of the People's Republic of China (http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd 94d329df351d7da8aefc2.shtml) and the Experts Consensus on Rational Clinical Drug Use in Guangdong for Treatment of Pneumonia Caused by COVID-19 issued by Guangdong Pharmacy Administration & Quality Control Center on 29th, February, 2020. Any inquiry of chloroquine,please contact Prof. Shanping Jiang (shanpingjiang@126.com).

At present, the epidemic in China is effectively contained. However, it shows a rapid increase around the world. The number of con firmed cases is climbing in many countries and regions. The epidemic becomes more and more severe. Truly empathizing with the people facing the epidemic in other countries, we stand ready to share our experiences and scienti fic achievements, deepen the international S&T cooperation, and offer as much assistance as we can. Let's form a strong concerted force to beat the disease.

There is a Chinese saying,“The going is difficult when doing it alone;the going becomes easier when doing it with many others.” The novel coronavirus epidemic gives the international community a profound inspiration that humanity should be seen as one community with a shared future. Let's look out for one another, and join hands to tackle the risks and challenges. The victory over the pandemic will surely come out in the near future.

Wish you happiness and good health!

Dr. Ruijun Wang

Vice-Chairman of the 22nd Session, UNCSTD Mayor of Shaoguan City, Guangdong Province, P.R.C Former Director General of Department of Science and Technology of Guangdong Province, P.R.C